A larger percentage of weight loss regained after an intensive lifestyle intervention was positively associated with certain cardiometabolic risk factors in type 2 diabetes.
Risk for stroke, death increased with each 10 mmol/mol increase in HbA1c level.
Risk for dying from heart attack, stroke higher among those with high blood pressure, diabetes and short sleep.
Findings showed that the combination of insulin and pioglitazone lowered all-cause mortality risk, and this combination therapy exerted beneficial effects on noncardiovascular deaths.
Individuals with poor and intermediate versus good health more likely to continue insulin use
Cardiorenal disease is commonly the first cardiovascular disease manifestation in patients with type 2 diabetes.
Findings seen among patients with heart failure, reduced ejection fraction, irrespective of diabetes
Risk lower for heart failure, but not major CV events, compared with new users of DPP4 inhibitors.
Linagliptin compared with glimepiride for risk for major cardiovascular events in T2DM with elevated CV risk
Rybelsus is the first glucagon-like peptide (GLP-1) available in a tablet formulation that is approved for once daily use